Floatz logo

Lorlatanib

Solid Tumors

PfizerPhase 3Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

927 Active assets in the Solid Tumors cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
LIDOCAINE
Medical College of Wisconsin
Phase 4BB
VITAMIN D
Tanta University
Phase 4BB

View all 50 →

Same molecule, other indications

Lorlatanib is also rated in:

cancerDormant
B
Indicative ·
60 / 100
View asset →
urothelial carcinomaDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →